http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
X, 417 p. 78 illus., 21 illus. in color. online resource.
The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands. This special volume book - for the first time focusing on the NOP receptor - is designed to serve as a useful reference, stimulate more research on the N/OFQ-NOP receptor system, and lead to more development of NOP-related ligands for several therapeutic applications.
PART I. The N/OFQ-NOP Receptor System -- 1. The History of N/OFQ and the NOP Receptor -- 2. NOP-Targeted Peptide Ligands -- 3. NOP-Targeted Nonpeptide Ligands -- 4. Pharmacological Assays for Investigating the NOP Receptor -- 5. Electrophysiological Actions of N/OFQ -- 6. NOP Receptor Signaling Cascades -- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor -- PART II. Biological Actions of NOP Ligands -- 8.NOP-Related Mechanisms in Pain and Analgesia -- 9. NOP-Related Mechanisms in Substance Use Disorders -- 10. NOP Receptor Ligands and Parkinson's Disease -- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders -- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory -- 13. N/OFQ-NOP System in Food Intake -- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation -- 15. N/OFQ-NOP System and Airways -- 16. Effects of NOP-Related Ligands in Nonhuman Primates -- PART III. First Clinical Studies with NOP Ligands -- 17. Nociceptin/Orphanin FQ and Urinary Bladder -- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors -- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094) -- 20. Correction to: Electrophysiological Actions of N/OFQ.
Handbook of Experimental Pharmacology, 254